Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032445038> ?p ?o ?g. }
- W2032445038 endingPage "493" @default.
- W2032445038 startingPage "486" @default.
- W2032445038 abstract "In the present study, we determined the frequency and intensity of MRP protein expression by monoclonal antibody immunohistochemistry in a series of 259 resected invasive primary breast carcinomas, and we evaluated MRP immunoreactivity in relation to patient and tumour characteristics, relapse-free (RFS) and overall survival (OS). The immunostaining was graded on a semiquantitative scale that ranged from (-) to ( ). Overall, 34% of the tumours were positive for anti-MRP antibody: 19% showed weak cytoplasmic staining (+), 14% had clear cytoplasmic staining (++) and only 1% of the tumours had a strong cytoplasmic as well as membranous staining ( ). MRP expression was not related to patient's age, menopausal status, tumour size, differentiation grade, oestrogen and progesterone receptor level or lymph node involvement. In an exploratory univariate analysis of all patients, only primary tumour size and number of lymph nodes involved were significantly associated with shortened RFS (P < 0.001 and P < 0.001 respectively) and OS (P = 0.02 and P < 0.001 respectively). In Cox univariate analysis for RFS in subgroups of patients stratified by menopausal status, tumour size, nodal status, adjuvant systemic therapy and oestrogen and progesterone receptor status, MRP expression was associated with increased risk for failure in patients with small tumours (T1), in node-negative patients and in node-positive patients who received adjuvant systemic chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF); the relative hazard rate (RHR) for relapse was increased in the presence of MRP, with RHR values with 95% confidence limits (CL) of 2.8 (1.2-6.9), 2.1 (1.0-4.2) and 2.8 (0.8-9.9) respectively. In analysis for OS, expression of MRP was also associated with increased risk for failure in patients with small tumours (T1) [RHR (95% CL) 2.3 (0.9-6.0)] and in node-positive patients who received adjuvant systemic chemotherapy with CMF [RHR (95% CL) 3.7 (0.8-17.1)] but not in node-negative patients [RHR (95% CL) 1.1 (0.4-2.6)]. In conclusion, our results show that MRP is frequently overexpressed in primary breast cancer and suggest that MRP expression might be of prognostic significance in the subgroups of patients with the more favourable prognosis, i.e. patients with small tumours and node-negative patients, as well as in the setting of adjuvant systemic chemotherapy. In primary breast cancer, MRP might be related to altered cell biological behaviour, including a more aggressive phenotype, and resistance to adjuvant systemic chemotherapy." @default.
- W2032445038 created "2016-06-24" @default.
- W2032445038 creator A5002402040 @default.
- W2032445038 creator A5016594673 @default.
- W2032445038 creator A5019431922 @default.
- W2032445038 creator A5037696756 @default.
- W2032445038 creator A5048953776 @default.
- W2032445038 creator A5051644644 @default.
- W2032445038 creator A5065210354 @default.
- W2032445038 creator A5066680524 @default.
- W2032445038 creator A5075444169 @default.
- W2032445038 creator A5085426388 @default.
- W2032445038 date "1997-08-01" @default.
- W2032445038 modified "2023-10-09" @default.
- W2032445038 title "The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer" @default.
- W2032445038 cites W1570640139 @default.
- W2032445038 cites W1583427298 @default.
- W2032445038 cites W1594873085 @default.
- W2032445038 cites W1595506167 @default.
- W2032445038 cites W1595867557 @default.
- W2032445038 cites W1815735775 @default.
- W2032445038 cites W1906680642 @default.
- W2032445038 cites W1972062962 @default.
- W2032445038 cites W2000662019 @default.
- W2032445038 cites W2004824373 @default.
- W2032445038 cites W2057305205 @default.
- W2032445038 cites W206710202 @default.
- W2032445038 cites W2067898376 @default.
- W2032445038 cites W2072826958 @default.
- W2032445038 cites W2074736392 @default.
- W2032445038 cites W2076714523 @default.
- W2032445038 cites W2092704724 @default.
- W2032445038 cites W2099212515 @default.
- W2032445038 cites W2099523743 @default.
- W2032445038 cites W2109579983 @default.
- W2032445038 cites W2121528021 @default.
- W2032445038 cites W2127819051 @default.
- W2032445038 cites W2138792907 @default.
- W2032445038 cites W2143071116 @default.
- W2032445038 cites W2150150931 @default.
- W2032445038 cites W2150541366 @default.
- W2032445038 cites W2152117655 @default.
- W2032445038 cites W2157897080 @default.
- W2032445038 cites W2167621975 @default.
- W2032445038 cites W2168070336 @default.
- W2032445038 cites W2231499661 @default.
- W2032445038 cites W2248842252 @default.
- W2032445038 cites W2399799438 @default.
- W2032445038 cites W2400978075 @default.
- W2032445038 cites W2413971895 @default.
- W2032445038 cites W2431955049 @default.
- W2032445038 cites W4238806036 @default.
- W2032445038 cites W2145653427 @default.
- W2032445038 doi "https://doi.org/10.1038/bjc.1997.414" @default.
- W2032445038 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2227995" @default.
- W2032445038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9275026" @default.
- W2032445038 hasPublicationYear "1997" @default.
- W2032445038 type Work @default.
- W2032445038 sameAs 2032445038 @default.
- W2032445038 citedByCount "136" @default.
- W2032445038 countsByYear W20324450382012 @default.
- W2032445038 countsByYear W20324450382013 @default.
- W2032445038 countsByYear W20324450382014 @default.
- W2032445038 countsByYear W20324450382015 @default.
- W2032445038 countsByYear W20324450382016 @default.
- W2032445038 countsByYear W20324450382017 @default.
- W2032445038 countsByYear W20324450382019 @default.
- W2032445038 countsByYear W20324450382020 @default.
- W2032445038 countsByYear W20324450382021 @default.
- W2032445038 countsByYear W20324450382022 @default.
- W2032445038 countsByYear W20324450382023 @default.
- W2032445038 crossrefType "journal-article" @default.
- W2032445038 hasAuthorship W2032445038A5002402040 @default.
- W2032445038 hasAuthorship W2032445038A5016594673 @default.
- W2032445038 hasAuthorship W2032445038A5019431922 @default.
- W2032445038 hasAuthorship W2032445038A5037696756 @default.
- W2032445038 hasAuthorship W2032445038A5048953776 @default.
- W2032445038 hasAuthorship W2032445038A5051644644 @default.
- W2032445038 hasAuthorship W2032445038A5065210354 @default.
- W2032445038 hasAuthorship W2032445038A5066680524 @default.
- W2032445038 hasAuthorship W2032445038A5075444169 @default.
- W2032445038 hasAuthorship W2032445038A5085426388 @default.
- W2032445038 hasBestOaLocation W20324450381 @default.
- W2032445038 hasConcept C121608353 @default.
- W2032445038 hasConcept C126322002 @default.
- W2032445038 hasConcept C142724271 @default.
- W2032445038 hasConcept C143998085 @default.
- W2032445038 hasConcept C144301174 @default.
- W2032445038 hasConcept C204232928 @default.
- W2032445038 hasConcept C207103383 @default.
- W2032445038 hasConcept C2778001805 @default.
- W2032445038 hasConcept C2780849966 @default.
- W2032445038 hasConcept C38180746 @default.
- W2032445038 hasConcept C4224716 @default.
- W2032445038 hasConcept C44249647 @default.
- W2032445038 hasConcept C530470458 @default.
- W2032445038 hasConcept C71924100 @default.
- W2032445038 hasConcept C84606932 @default.